FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897793711> ?p ?o ?g. }

• W2897793711 endingPage "e57" @default.
• W2897793711 startingPage "e57" @default.
• W2897793711 abstract "Treatment of centrally located hepatocellular carcinoma (CL-HCC) with stereotactic body radiation therapy (SBRT) remains a significant challenge for radiation oncologists managing this disease. Currently, there is paucity of data on hepatobiliary toxicity (HBT) and clinical outcomes after irradiation of CL-HCC. This study aimed to assess safety and efficacy of SBRT for CL-HCC. We identified 53 patients with CL-HCC treated with SBRT in the period of 2011-2017 in our institution. CL-HCC was defined as a tumor sited in segments 4, 5, or 8, adjacent to the hepatic hilum, or <1 cm from main portal branches. Primary endpoints were treatment response (TR), local control (LC), and HBT. TR was assessed using Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Secondary endpoints included disease progression outside of SBRT treatment field, disease-specific survival (DSS), and overall survival (OS). LC and survival were examined using the Kaplan-Meier and log-rank methods. HBTs were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Multivariable logistic regression models were used to evaluate for predictors of grade ≥3 AEs. Median age was 65 years. 33 (62.3%) patients had Child-Turcotte-Pugh (CTP) score A, 20 (37.77%) - score B. Albumin-Bilirubin (ALBI) grade 1 constituted 6 (11.3%) cases, grade 2 – 32 (60.4%), grade 3 – 15 (28.3%). The majority of patients had pre-treatment AFP ≤500 - 37 (69.8%), and tumor ≤50 mm – 42 (79.3%). A median total dose of 40 Gy was delivered in a median of 5 fractions. Median BED3 and BED10 were 146.7 Gy and 72 Gy, respectively. Complete/partial response was observed in 40 (75.5%) lesions, stable disease - in 9 (17.0%), and progression – in 4 (7.5%). At a median follow-up of 12.2 months, there were 6 (11.3%) local failures. The actuarial 2-year LC rate was 87.9%. LC was better with higher BED10 (>70 vs ≤70 Gy) 96.9% vs 72.5%, p=0.01, and among non-Hispanic 92.9% vs 66.7% Hispanic patients, p=0.03. LC rates did not differ between pre-treatment ALBI grades, CTP scores, or AFP (≤500 vs >500). At the time of analysis, 26 (49.1%) patients developed disease progression outside of SBRT field. A total of 30 (56.6%) deaths were recorded; 20 (37.7%) patients died of HCC. The 2-year rates for disease progression outside of SBRT field, DSS, and OS rates were 44.5%, 53.2%, and 39.1%, respectively. The incidence of any Grade ≥3 AE was 17.0% (9 of 53), most of which (n=6) were grade 3. There were no grade 5 AEs. Five of 9 AEs were acute (≤ 60 days). There was a trend toward an increased risk of grade ≥3 AE with mean liver dose >10 Gy (OR 8.46, p=0.07). In the present cohort, the majority of patients had pre-treatment CTP score A, ALBI grade ≤2, AFP ≤500, and tumors ≤50 mm. In this context, SBRT to a total median dose of 40 Gy produced excellent TR with relatively favorable side effect profile and LC. Select HCC patients who are not candidates for surgery or other locoregional therapies can be considered for SBRT to the central liver." @default.
• W2897793711 created "2018-10-26" @default.
• W2897793711 creator A5005427785 @default.
• W2897793711 creator A5010688246 @default.
• W2897793711 creator A5012665897 @default.
• W2897793711 creator A5037656123 @default.
• W2897793711 creator A5072463488 @default.
• W2897793711 date "2018-11-01" @default.
• W2897793711 modified "2023-09-30" @default.
• W2897793711 title "Stereotactic Body Radiation Therapy for Centrally Located Hepatocellular Carcinoma: Outcomes and Toxicities" @default.
• W2897793711 doi "https://doi.org/10.1016/j.ijrobp.2018.07.482" @default.
• W2897793711 hasPublicationYear "2018" @default.
• W2897793711 type Work @default.
• W2897793711 sameAs 2897793711 @default.
• W2897793711 citedByCount "0" @default.
• W2897793711 crossrefType "journal-article" @default.
• W2897793711 hasAuthorship W2897793711A5005427785 @default.
• W2897793711 hasAuthorship W2897793711A5010688246 @default.
• W2897793711 hasAuthorship W2897793711A5012665897 @default.
• W2897793711 hasAuthorship W2897793711A5037656123 @default.
• W2897793711 hasAuthorship W2897793711A5072463488 @default.
• W2897793711 hasBestOaLocation W28977937111 @default.
• W2897793711 hasConcept C126322002 @default.
• W2897793711 hasConcept C126838900 @default.
• W2897793711 hasConcept C143998085 @default.
• W2897793711 hasConcept C197934379 @default.
• W2897793711 hasConcept C203092338 @default.
• W2897793711 hasConcept C2776694085 @default.
• W2897793711 hasConcept C2777793932 @default.
• W2897793711 hasConcept C2778019345 @default.
• W2897793711 hasConcept C2778822529 @default.
• W2897793711 hasConcept C2779819216 @default.
• W2897793711 hasConcept C2779984678 @default.
• W2897793711 hasConcept C535046627 @default.
• W2897793711 hasConcept C71924100 @default.
• W2897793711 hasConcept C90924648 @default.
• W2897793711 hasConceptScore W2897793711C126322002 @default.
• W2897793711 hasConceptScore W2897793711C126838900 @default.
• W2897793711 hasConceptScore W2897793711C143998085 @default.
• W2897793711 hasConceptScore W2897793711C197934379 @default.
• W2897793711 hasConceptScore W2897793711C203092338 @default.
• W2897793711 hasConceptScore W2897793711C2776694085 @default.
• W2897793711 hasConceptScore W2897793711C2777793932 @default.
• W2897793711 hasConceptScore W2897793711C2778019345 @default.
• W2897793711 hasConceptScore W2897793711C2778822529 @default.
• W2897793711 hasConceptScore W2897793711C2779819216 @default.
• W2897793711 hasConceptScore W2897793711C2779984678 @default.
• W2897793711 hasConceptScore W2897793711C535046627 @default.
• W2897793711 hasConceptScore W2897793711C71924100 @default.
• W2897793711 hasConceptScore W2897793711C90924648 @default.
• W2897793711 hasIssue "3" @default.
• W2897793711 hasLocation W28977937111 @default.
• W2897793711 hasOpenAccess W2897793711 @default.
• W2897793711 hasPrimaryLocation W28977937111 @default.
• W2897793711 hasRelatedWork W1994435019 @default.
• W2897793711 hasRelatedWork W2037572837 @default.
• W2897793711 hasRelatedWork W2141443930 @default.
• W2897793711 hasRelatedWork W2742460075 @default.
• W2897793711 hasRelatedWork W2752827782 @default.
• W2897793711 hasRelatedWork W2782745674 @default.
• W2897793711 hasRelatedWork W2791249304 @default.
• W2897793711 hasRelatedWork W3016104851 @default.
• W2897793711 hasRelatedWork W3031099491 @default.
• W2897793711 hasRelatedWork W4283763477 @default.
• W2897793711 hasVolume "102" @default.
• W2897793711 isParatext "false" @default.
• W2897793711 isRetracted "false" @default.
• W2897793711 magId "2897793711" @default.
• W2897793711 workType "article" @default.